Stocks · News reference
Citizens Downgrades Cellectis to Market Perform
Citizens analyst Silvan Turkcan downgrades Cellectis (NASDAQ:CLLS) from Market Outperform to Market Perform.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
This Nu Holdings Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday
Analysts downgraded NU, BAK, CLLS and CBZ; price targets for NU, BAK and CLLS were cut sharply.
Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday
Analysts raised targets for RAPP, ALLR, UNP and ALVO; cut targets for NU, CLLS and JBHT, with several rating upgrades and downgrades.
Barclays Downgrades Cellectis to Underweight, Lowers Price Target to $1.3
Barclays analyst Lukas Shumway downgrades Cellectis (NASDAQ:CLLS) from Overweight to Underweight and lowers the price target from $9 to $1.3.